AGAurileya de Jesus Gouveia

Aurileya de Jesus Gouveia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aurileya de Jesus Gouveia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospecção Tecnológica de Patentes sobre Extratos Vegetais para Leishmaniose Cutânea: lacunas e oportunidades de inovação

    by Aurileya de Jesus Gouveia, Maria Clara Camilo da Silva, Carolina Bioni Garcia Teles, Minelly Azevedo da Silva

    A leishmaniose cutânea (LC) é uma doença negligenciada com elevada incidência no Brasil, e a biodiversidade representa fonte pouco explorada para terapias inovadoras. Apesar da relevância epidemiológica e dos avanços com extratos vegetais, existe uma lacuna entre a produção científica e a proteção intelectual, refletida no baixo número de patentes, sobretudo nacionais. Este estudo objetivou: (i) mapear patentes sobre extratos vegetais no tratamento da LC; (ii) identificar lacunas tecnológicas e oportunidades de inovação; e (iii) propor estratégias para fortalecer a proteção intelectual de ativos naturais. A metodologia consistiu em prospecção tecnológica nas bases INPI, Espacenet e Patentscope (2008-2025), com descritores e códigos IPC/CPC. As patentes foram triadas por relevância terapêutica, exclusão de duplicatas e categorização. Foram identificadas 18 patentes, três no INPI, com predominância de formulações tópicas. Os resultados evidenciam descompasso entre produção acadêmica e proteção intelectual, além da sub-representação da biodiversidade brasileira, reforçando a importância de políticas integradas.

  • Synthesis of New Bi-Triazoles with Plasmocide Action Against Plasmodium falciparum

    by Dinesh Addla, Cristiane Diniz, Quelli Larissa Oliveira de Santana, Leandro Do Nascimento Martinez, Marcinete Latorre Almeida, Minelly Azevedo da Silva, Welington da Silva Paula Do Nascimento, Aurileya de Jesus Gouveia, Saara Neri Fialho, Amália dos Santos Ferreira, et al.

    Background: A series of bi-triazoles conjugates 1,2,3 and 1,2,4 was synthesized with an aim to study the evaluation of the antimalarial profile of families of triazole derivatives. The study used the W2 strain of Plasmodium falciparum (Chloroquine-Resistant), to determine the inhibitory concentration of 50% of the parasites (IC50) and HepG2 cells to describe the cytotoxic concentration for 50% of the cells (CC50). Among the study classes, bi-triazoles stood out with IC50 values between 8.9 to 0.45 μM; highlighted the compound 14d (IC50 of 0.45 ± 0.02 μM) with the most promising result. Regarding the cytotoxic concentration, all compounds that presented IC50 values ≤ 100 μM were evaluated. Three compounds stood out as the highest selectivity index (SI) values, 14b (SI ˃111.1), 13d (SI ˃111.1) and 14d (SI ˃1.111). Such results expose the importance of working with classes of molecules that allow rapid synthesis and dispositions for structural changes. Highlighting the evolution of the IC50 values of the compounds, when adding the second triazole block. Thus, the results found in this study, have the possibility of choosing new molecules for the treatment of malaria. Objective: This work was to synthesize a series of bi-triazole conjugates 1,2,3 and 1,2,4-triazole moiety and evaluate their activities against Plasmodium falciparum. Methods: The bi-triazole was synthesized in a 3-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. For the in vitro antiplasmodial assays, the SYBR Green fluorimetric technique and the W2 strain were used, where an IC50 (Inhibitory Concentration) value was obtained for each compound. The compounds were also evaluated for their stagespecificity and speed of action (W2 strain). Safety tests were performed to determine the hemolytic and cytotoxic action of the evaluated compounds. In these tests, the cell lines HepG2 and VERO were used, and the cytotoxicity was evaluated by the MTT technique. This allowed the CC50 values to be obtained (Cytotoxic Concentration). Subsequently, the Selectivity Index (SI) was calculated for each compound. Results: The newly synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial compounds. In general, the bi-triazoles with trifluoromethyl group present at 1,2,4-triazole moiety proved to be more potent regarding antiplasmodial activity. Conclusion: The synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial agents.


  • Natural and Semisynthetic Triterpenes from Combretum leprosum Mart. with Antiplasmodial Activity

    by Guilherme Passarini, Amália Ferreira, Leandro Moreira-Dill, Fernando Zanchi, Aurileya de Jesus, Valdir Facundo, Carolina Teles

    Malaria is responsible for thousands of deaths each year. Currently, artemisinin combination therapy (ACT) is used as first-choice medication against the disease. However, the emergence of resistant strains prompts the search for alternative compounds. The present study aimed to investigate the antiplasmodial activities of natural triterpenes (compounds 1 and 2), and semisynthetic derivatives 1a, 1b, 1c, and 1d. Antiplasmodial assays were carried out using the SYBR Green technique, whereas cytotoxicity was evaluated by the MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide) method. Hemolytic assays were performed on human erythrocytes. An in silico analysis of the compounds against PfENR (Plasmodium falciparum 2-trans-enoyl-reductase) was carried out by molecular docking. Experiments with 1, and its derivatives against P. falciparum showed that 1a was very similar in terms of biological activity to compound 1 (half maximal inhibitory concentration (IC50) ca. 4 μM), whereas 1b, 1c, and 1d had reduced antiplasmodial activities (IC50 between 8-103 μM). The selectivity indexes of 1 and 1d for HepG2, and Vero cells were > 10. Docking results partially agreed with the in vitro experiments, with 1 and 1c having the best and worst affinities with PfENR, respectively. In conclusion, the results showed that 1 and 1d may serve as biotechnological tools in the development of antimalarial drugs.